---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-24-000990"
form_type: "8-K"
ticker: "ARCT"
cik: "0001768224"
company_name: "Arcturus Therapeutics Holdings Inc."
filed_at: "2024-08-05T23:59:59+00:00"
generated_at: "2026-05-31T13:11:25.251530+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Arcturus Q2 revenue $49.9M, net loss $17.2M; pipeline advances, Kostaive launch on track

## Summary
- Revenue $49.9M, up $39.4M YoY from $10.5M, driven by CSL collaboration revenue.
- Net loss $17.2M ($0.64 per share) improved from $52.6M loss in Q2 2023.
- Cash $317.2M; cash runway extends through Q1 2027; $437.1M received from CSL to date.
- IND submitted for ARCT-032 Phase 2 cystic fibrosis study; ARCT-810 OTC deficiency interim data expected Q4 2024.
- Kostaive on track for Q4 commercial launch in Japan; EMA review ongoing; COVID/flu programs with CSL progressing.

## SEC filing metadata
- accession: 0001193805-24-000990
- form_type: 8-K
- ticker: ARCT
- cik: 0001768224
- company_name: Arcturus Therapeutics Holdings Inc.
- filed_at: 2024-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768224/000119380524000990/0001193805-24-000990-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768224/000119380524000990/e663815_8k-arct.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-24-000990
- JSON: https://secwatch.observer/filing/0001193805-24-000990.json
- Plain text: https://secwatch.observer/filing/0001193805-24-000990.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.